Clinical significance of the determination of angiogenic factors

European Journal of Cancer Part A

Volumn 32, Issue 14, 1996, Pages 2513-2519

  Toi, M ^a   Taniguchi, T ^a   Yamamoto, Y ^a   Kurisaki, T ^a   Suzuki, H ^b   Tominaga, T ^a  

^a TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^b Base Technology Center   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIAL CELL GROWTH FACTOR;

ANGIOGENESIS; GENE EXPRESSION; HUMAN; LYMPHOCYTE; MACROPHAGE; MICROVASCULATURE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SOLID TUMOR; TUMOR GROWTH;

EID: 0030498430     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(96)00397-8     Document Type: Article

References (63)

1. 1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med 1995, 1, 27-31.
2. 2. Kieser A, Weich HA, Brandner G, Marme D, Kolch W. Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene 1994, 9, 963-969.
3. 3. Rak J, Mitsuhashi Y, Bayko L, et al. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res 1995, 55, 4575-4580.
4. 4. Mukhopadhyay D, Tsiokas L, Sukhatme VP. Wild-type p53 and v-src exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res 1995, 55, 6161-6165.
5. 5. Dameron KM, Volpert OV, Tainsky MS, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994, 265, 1582-1584.
6. 6. Gasparini G, Harris AL. Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool. J Clin Oncol 1995, 13, 765-782.
7. 7. Toi M, Inada K, Suzuki H, Tominaga T. Tumor angiogenesis in breast cancer: its importance as a prognostic indicator and the association with vascular endothelial growth factor expression. Breast Cancer Res Treat 1995, 36, 193-204.
8. 8. O'Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nature Med 1996, 2, 689-692.
9. 9. Plate KH, Breier G, Risau W. Molecular mechanisms of developmental and tumor angiogenesis. Brain Pathol 1994, 4, 207-218.
10. 10. Ferrara N. The role of vascular endothelial growth factor in pathological angiogenesis. Breast Cancer Res Treat 1995, 36, 127-137.
11. 11. Toi M, Hoshina S, Takayanagi T, Tominaga T. Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer. Jpn J Cancer Res 1994, 85, 1045-1049.
12. 12. Ishikawa F, Miyazono K, Hellman U, et al. Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. Nature 1989, 338, 557-562.
13. 13. Furukawa T, Yoshimura A, Sumizawa T, Haraguchi M, Akiyama S. Angiogenic factor. Nature 1992, 356, 668.
14. 14. Moghaddam A, Zhang H-T, Fan T-PD, et al. Thymidine phosphorylase is angiogenic and promotes tumor growth. Proc Natl Acad Sci USA 1995, 92, 998-1002.
15. 15. Gruber BL, Marchese MJ, Kew R. Angiogenic factors stimulate mast-cell migration. Blood 1995, 86, 2488-2493.
16. 16. Toi M, Hoshina S, Taniguchi T, Yamamoto Y, Ishitsuka H, Tominaga T. Expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human breast cancer. Itn J Cancer 1995, 64, 79-82.
17. 17. Haraguchi M, Miyadera K, Uemura K, et al. Angiogenic activity of enzymes. Nature 1994, 368, 198.
18. 18. Toi M, Inada K, Hoshina S, Suzuki H, Kondo S, Tominaga T. Vascular endothelial growth factor and platelet-derived endothelial cell growth factor are frequently coexpressed in highly vascularized human breast cancer. Clin Cancer Res 1995, 1, 961-964.
19. 19. Samoto K, Ikezaki K, Ono M, et al. Expression of vascular endothelial growth factor and its possible relation with neovascularization in human brain tumors. Cancer Res 1995, 55, 1189-1193.
20. 20. Guidi AJ, Abu-Jawdeh G, Berse B, et al. Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia. J Natl Cancer Inst 1995, 87, 1237-1245.
21. 21. Mattern J, Koomagi R, Volm M. Vascular endothelial growth factor expression and angiogenesis in non-small cell lung carcinomas. Int Oncol 1995, 6, 1059-1062.
22. 22. Maeda K, Chung Y-S, Ogawa Y, et al. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 1996, 77, 858-863.
23. 23. Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 1995, 55, 3964-3968.
24. 24. Brown LF, Berse B, Jackman RW, et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Human Pathol 1995, 26, 86-91.
25. 25. Plate KH, Breier G, Millauer B, Ullrich A, Risau W. Up-regulation of vascular endothelial growth and its cognate receptors in a rat glioma model of tumor angiogenesis. Cancer Res 1993, 53, 5822-5827.
26. 26. Brown LF, Berse B, Jackman RW, et al. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am J Pathol 1993, 143, 1255-1262.
27. 27. Boocock CA, Charnock-Jones DS, Sharkey AM, et al. Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J Natl Cancer Inst 1995, 87, 506-516.
28. 28. Maeda K, Chung Y-S, Ogawa Y, et al. Thymidine phosphorylase/platelet-derived endothelial cell growth factor expression associated with hepatic metastasis in gastric carcinoma. Br J Cancer 1996, 73, 884-888.
29. 29. Takebayashi Y, Yamada K, Sumizawa T, Miyadera K, Aikou T, Takiyama S. Clinicopathological significance of angiogenic enzyme, thymidine phosphorylase (dThdPase), in colorectal carcinoma. AACR Proceedings 1995, 90.
30. 30. Reynolds K, Farzaheh F, Collins WP, et al. Association of ovarian malignancy with expression of platelet-derived endothelial cell growth factor. J Natl Cancer Inst 1994, 86, 1234-1238.
31. 31. Fox SB, Westwood M, Moghaddam A, et al. The angiogenic factor platelet-derived endothelial cell growth factor/thymidine phosphorylase is up-regulated in breast cancer epithelium and endothelium. Br J Cancer 1996, 73, 275-280.
32. 32. O'Brien T, Cranston D, Fuggle S, Bicknell R, Harris AL. Differential angiogenic pathways characterize superficial and invasive bladder cancer. Cancer Res 1995, 55, 510-513.
33. 33. Toi M, Kondo S, Suzuki H, et al. Quantitative analysis of vascular endothelial growth factor in primary breast cancer. Cancer 1996, 77, 1101-1106.
34. 34. Bicknell R, Harris A. Novel growth regulatory factors and tumour angiogenesis. Eur J Cancer 1991, 27, 781-784.
35. 35. Luqmani YA, Coombes RC. Expression of basic fibroblast growth factor, FGFR1 and FGFR2 in normal and malignant human breast, and comparison with other normal tissues. Br J Cancer 1992, 66, 273-280.
36. 36. Hildenbrand R, Dilger I, Horlin A, Stutte HJ. Urokinase and macrophages in tumour angiogenesis. Br J Cancer 1995, 72, 818-823.
37. 37. Naldini L, Tamagnone L, Vigna E. Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor. EMBO J 1992, 11, 4825-4833.
38. 38. Pepper MS, Ferrara N, Orci L, Montesano R. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun 1992, 189, 824-831.
39. 39. Stavri GT, Zachary IC, Baskerville PA, Martin JF, Erusalimsky JD. Basic fibroblast growth factor upregulates the expression of vascular endothelial growth factor in vascular smooth muscle cells: synergistic interaction with hypoxia. Circulation 1995, 92, 11-14.
40. 40. Nanus DM, Schmitz-Drager BJ, Motzer RJ, et al. Expression of basic fibroblast growth factor in primary human renal tumors correlation with poor survival. J Natl Cancer Inst 1993, 85, 1597-1599.
41. 41. Visscher DW, DeMattia F, Ottosen S, Sarkar FH, Crissman JD. Biologic and clinical significance of basic fibroblast growth factor immunostaining in breast carcinoma. Modern Pathol 1995, 8, 665-670.
42. 42. Haraguchi M, Furukawa T, Sumizawa T, Akiyama S. Sensitivity of human KB cells expressing platelet-derived endothelial cell growth factor to pyrimidine antimetabolites. Cancer Res 1993, 53, 5680-5682.
43. 43. Schwartz EL, Baptiste N, Wadler S, Makower D. Thymidine phosphorylase mediates the sensitivity of human colon carcinoma cells to 5-fluorouracil. J Biol Chem 1995, 270, 19073-19077.
44. 44. Patterson AV, Zhang H, Moghaddam A, et al. Increased sensitivity to the prodrug 5′-deoxy-5-fluorouridine and modulation of 5-fluoro-2′-deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase. Br J Cancer 1995, 72, 669-675.
45. 45. Toi M. Endothelial growth factors: a target for antiangiogenesis. Cancer J 1995, 8, 315-319.
46. 46. Yamashita J, Ogawa M, Yamashita S, et al. Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer. Cancer Res 1994, 54, 1630-1633.
47. 47. O'Brien T, Cranston D, Fuggle S, Bicknell R, Harris AL. The angiogenic factor midkine is expressed in bladder cancer, and overexpression correlates with a poor outcome in patients with invasive cancers. Cancer Res 1996, 56, 2515-2518.
48. 48. Foekens JA, van Putten WLJ, Portengen H, et al. Prognostic value of PS2 and cathepsin D in 710 human primary breast tumors: multivariate analysis. J Clin Oncol 1993, 11, 899-908.
49. 49. Foekens JA, Buessecker F, Peters HA, et al. Plasminogen activator inhibitor-2: prognostic relevance in 1012 patients with primary breast cancer. Cancer Res 1995, 55, 1423-1427.
50. 50. Fujimoto K, Ichimori Y, Kakizoe T. Increased serum levels of basic fibroblast growth factor in patients with renal cell carcinoma. Biochem Biophys Commun 1991, 180, 386-392.
51. 51. Fujimoto K, Ichimori Y, Yamaguchi H, et al. Basic fibroblast growth factor as a candidate tumor marker for renal cell carcinoma. Jpn J Cancer Res 1995, 86, 182-186.
52. 52. Sliutz G, Tempfer C, Obermair A, Reinthaller A, Gitsch G, Kainz C. Serum evaluaton of basic fibroblast growth factor in cervical cancer patients. Cancer Lett 1995, 94, 227-231.
53. 53. Deunsing S, Grosse J, Atzpodien J. Increased serum levels of basic fibroblast growth factor (nFGF) are associated with progressive lung metastases in advanced renal cell carcinoma patients. Anticancer Res 1995, 15, 2331-2333.
54. 54. Nguyen M, Watanabe H, Budson AE, Richie JP, Folkman J. Elevated levels of the angiogenic peptide basic fibroblast growth factor in urine of bladder cancer patients. J Natl Cancer Inst 1993, 85, 241-243.
55. 55. Kondo S, Asano M, Matsuo K, Ohmori I, Suzuki H. Vascular endothelial growth factor/vascular permeability factor is detectable in the sera of tumor-bearing mice and cancer patients, Biochim Biophys Acta 1994, 1221, 211-214.
56. 56. Yamamoto Y, Toi M, Kondo S, et al. Concentrations of vascular endothelial growth factor in sera of normal control and cancer patients. Clin Cancer Res 1996, 2, 821-826.
57. 57. Taniguchi T, Toi M, Inada K, Imazawa T, Yamamoto Y, Tominaga T. Serum concentrations of hepatocyte growth factor in breast cancer patients. Clin Cancer Res 1995, 1, 1031-1034.
58. 58. Moskal TL, Huang S, Ellis LM, Fritsche HA Jr, Chakrabarty S. Serum levels of transforming growth factor alpha in gastrointestinal cancer patients. Cancer Epidemiol, Biomarkers & Prevention 1995, 4, 127-131.
59. 59. Chakrabarty S, Huang S, Moskal TL, Fritsche HA Jr. Elevated serum levels of transforming growth factor-alpha in breast cancer patients. Cancer Lett 1994, 79, 157-160.
60. r 92,000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer. Cancer Res 1993, 53, 140-146.
61. 61. Jarosz DE, Hamer PJ, Tenney DY, Zabrecky JR. Elevated levels of pro-cathepsin D in the plasma of breast cancer patients. Int J Oncol 1995, 6, 859-865.
62. 62. Kakkar AK, DeRuvo N, Chinswangwatanakul V, Tebbutt S, Williamson RCN. Extrinsic-pathway activation in cancer with high factor VIIa and tissue factor. Lancet 1995, 346, 1004-1005.
63. 63. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Med 1995, 1, 149-153.